Monday, September 21, 2020 1:20:54 AM
Well that takes away three worries. 1. What the financial agreement with NeuroRx actually looks like. 2. Will they merge. 3. Will rights be sold, excluding Relief's shareholders from future profits. All in all a very fair agreement that incentivises both sides. I read this as Relief and NeuroRx are in it for the long haul and aren't necessarily planning on selling yet. Will be losing 1/2 of the US/Canada/Israeli market, but weighted heavily in favor of Relief for the rest of the world. Good news overall as far as I'm concerned.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
